Items tagged with Drug-resistant TB
TB CAB Statement (post with simple image)
TB CAB Access Considerations Statement Regarding Johnson & Johnson Announcement of Bedaquiline Price Reduction
TAG launches two new TB Activist Guides (post with simple image)
Treatment Action Group launches two new TB Activist Guides: An Activist’s Guide to Tuberculosis Diagnostic Tools, and An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis.
TB REACH Wave 9 now open for proposals (post with simple image)
Wave 9 to address shortcomings in drug-resistant TB care - linkage to care, uptake of novel treatment regimens and treatment outcomes.
International support for compulsory license to address access barriers to life-saving TB medicines (post with simple image)
Advocates urge the Indian government to issue compulsory licenses for patents on bedaquiline and delamanid to make the drugs more affordable and accessible.
Advocates call on Indian government to stop using injectable agents for the treatment of drug-resistant TB (post with simple image)
Advocates urge the Indian government to stop using kanamycin for the treatment of drug-resistant TB and instead scale up access to all oral regimens.
Key changes to the treatment of drug-resistant TB (post with simple image)
The World Health Organization issues rapid communication on updated guidance for the treatment of drug-resistant TB.
Activists across the world demand urgent action to improve access to lifesaving TB medicine, bedaquiline (post with simple image)
Communities affected by TB everywhere have a right to benefit from scientific progress, including access to short-course, bedaquiline-based treatment regimens for drug-resistant TB.
Field guide for managing drug-resistant TB in pregnant and peripartum people (post with simple image)
The Sentinel Project on Pediatric Drug-Resistant Tuberculosis releases a guide meant to support the care of pregnant and peripartum people with drug-resistant TB and the neonates born to them.
Response to TB treatment trials results published and presented during the 2022 Union World Conference on Lung Health (post with simple image)
Statement by Treatment Action Group (TAG) and the Global Tuberculosis Community Advisory Board (TB CAB)
New MSF report warns that major opportunity to increase access to newer, safer DR-TB drugs is at risk (post with simple image)
With newer TB drugs to go off patent in 2023, MSF calls on Johnson & Johnson, Otsuka, and TB Alliance to remove additional barriers blocking generic manufacturers from entering the market.
Page 114 of 117 · Total posts: 0
←First 113 114 115 Last→